NASDAQ:FATE - Fate Therapeutics Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $18.74 -0.81 (-4.14 %) (As of 05/20/2019 07:30 AM ET)Previous Close$19.55Today's Range$18.22 - $19.5052-Week Range$8.64 - $20.04Volume1.24 million shsAverage Volume762,116 shsMarket Capitalization$1.22 billionP/E RatioN/ADividend YieldN/ABeta1.96 ProfileAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Fate Therapeutics, Inc. operates as a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorder. The firm programme cellular therapeutics for the treatment of life threatening diseases, hematologic malignancies, genetic disorders and diseases resulting from the dysregulation of the immune system. Its products include ProHema, ProTmune, Adaptive NK, iPSC-derived NK, Programmed CD34 and T cell therapy. The company was founded by Philip Beachy, Sheng Ding, Rudolf Jaenisch, Randall T. Moon, Michael Rudnicki, David Scadden, Leonard Zon, Alexander Rives, Scott Wolchko and John D. Mendlein on April 27, 2007 and is headquartered in San Diego, CA. Receive FATE News and Ratings via Email Sign-up to receive the latest news and ratings for FATE and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:FATE Previous Symbol CUSIPN/A CIK1434316 Webwww.fatetherapeutics.com Phone858-875-1800Debt Debt-to-Equity Ratio0.26 Current Ratio6.40 Quick Ratio6.40Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$4.74 million Price / Sales257.73 Cash FlowN/A Price / Cash FlowN/A Book Value$2.24 per share Price / Book8.37Profitability EPS (Most Recent Fiscal Year)($1.19) Net Income$-66,600,000.00 Net Margins-1,138.12% Return on Equity-54.30% Return on Assets-39.20%Miscellaneous Employees104 Outstanding Shares65,190,000Market Cap$1.22 billion Next Earnings Date8/5/2019 (Estimated) OptionableOptionable Fate Therapeutics (NASDAQ:FATE) Frequently Asked Questions What is Fate Therapeutics' stock symbol? Fate Therapeutics trades on the NASDAQ under the ticker symbol "FATE." How were Fate Therapeutics' earnings last quarter? Fate Therapeutics Inc (NASDAQ:FATE) posted its quarterly earnings results on Tuesday, May, 7th. The biopharmaceutical company reported ($0.30) EPS for the quarter, missing the consensus estimate of ($0.23) by $0.07. The biopharmaceutical company earned $2.63 million during the quarter, compared to analyst estimates of $2.01 million. Fate Therapeutics had a negative net margin of 1,138.12% and a negative return on equity of 54.30%. Fate Therapeutics's revenue for the quarter was up 156.3% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.27) EPS. View Fate Therapeutics' Earnings History. When is Fate Therapeutics' next earnings date? Fate Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, August 5th 2019. View Earnings Estimates for Fate Therapeutics. What price target have analysts set for FATE? 8 equities research analysts have issued 1-year price targets for Fate Therapeutics' stock. Their predictions range from $12.00 to $24.00. On average, they expect Fate Therapeutics' stock price to reach $19.6250 in the next twelve months. This suggests a possible upside of 4.7% from the stock's current price. View Analyst Price Targets for Fate Therapeutics. What is the consensus analysts' recommendation for Fate Therapeutics? 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Fate Therapeutics in the last year. There are currently 1 hold rating and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Fate Therapeutics. What are Wall Street analysts saying about Fate Therapeutics stock? Here are some recent quotes from research analysts about Fate Therapeutics stock: 1. According to Zacks Investment Research, "Fate Therapeutics, Inc. is a biopharmaceutical company. The company focused on the discovery and development of adult stem cell modulators to treat hematologic malignancies, lysosomal storage disorders and muscular dystrophies. Fate Therapeutics, Inc. is headquartered in San Diego, California. " (5/10/2019) 2. HC Wainwright analysts commented, "Our $12 price target is based on a sum-of-the-parts analysis based on probability-adjusted revenue forecasts for ProTmune and FATE-NK100. We use the net present value of our revenue forecast through 2026, apply a 40% probability of success for 2Q18 fully diluted net cash estimate of $0.84/share to arrive at our $12 price target. We value the early stage pipeline and Juno collaboration at $2.32/share. We assume a 25% discount rate for the NPV of the pipeline and a P/S multiple of 4x." (8/7/2018) Has Fate Therapeutics been receiving favorable news coverage? Headlines about FATE stock have been trending positive recently, according to InfoTrie Sentiment Analysis. The research firm identifies positive and negative press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Fate Therapeutics earned a news impact score of 2.3 on InfoTrie's scale. They also assigned headlines about the biopharmaceutical company a news buzz of 9.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the company's share price in the near term. Who are some of Fate Therapeutics' key competitors? Some companies that are related to Fate Therapeutics include argenx (ARGX), Spark Therapeutics (ONCE), Ablynx (ABLYF), China Biologic Products (CBPO), Allogene Therapeutics (ALLO), Repligen (RGEN), Halozyme Therapeutics (HALO), Acceleron Pharma (XLRN), Crispr Therapeutics (CRSP), Denali Therapeutics (DNLI), Iovance Biotherapeutics (IOVA), Aerie Pharmaceuticals (AERI), Audentes Therapeutics (BOLD), Regenxbio (RGNX) and Orchard Therapeutics (ORTX). What other stocks do shareholders of Fate Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Fate Therapeutics investors own include Energous (WATT), Juno Therapeutics (JUNO), Sorrento Therapeutics (SRNE), Sangamo Therapeutics (SGMO), Array Biopharma (ARRY), Neurocrine Biosciences (NBIX), Ocular Therapeutix (OCUL), Rigel Pharmaceuticals (RIGL), TG Therapeutics (TGTX) and Verastem (VSTM). Who are Fate Therapeutics' key executives? Fate Therapeutics' management team includes the folowing people: J. Scott Wolchko, President, Chief Executive Officer & DirectorDaniel D. Shoemaker, Chief Scientific OfficerYu Waye Chu, Vice President-Clinical DevelopmentJim Beitel, Senior Vice President-Corporate DevelopmentBahram Valamehr, Chief Development Officer Who are Fate Therapeutics' major shareholders? Fate Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional investors include FMR LLC (10.81%), BlackRock Inc. (7.98%), Victory Capital Management Inc. (3.04%), Polaris Venture Management Co. V L.L.C. (2.26%), Arch Venture Corp (1.95%) and Westfield Capital Management Co. LP (1.37%). Company insiders that own Fate Therapeutics stock include Amir Nashat, Cindy Tahl, Daniel D Shoemaker, J Scott Wolchko and Redmile Group, Llc. View Institutional Ownership Trends for Fate Therapeutics. Which institutional investors are selling Fate Therapeutics stock? FATE stock was sold by a variety of institutional investors in the last quarter, including Arch Venture Corp, Polaris Venture Management Co. V L.L.C., FMR LLC, Morgan Stanley, Westfield Capital Management Co. LP, JPMorgan Chase & Co., Columbus Circle Investors and Citigroup Inc.. Company insiders that have sold Fate Therapeutics company stock in the last year include Amir Nashat, Cindy Tahl, Daniel D Shoemaker and J Scott Wolchko. View Insider Buying and Selling for Fate Therapeutics. Which institutional investors are buying Fate Therapeutics stock? FATE stock was bought by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Jennison Associates LLC, BlackRock Inc., Federated Investors Inc. PA, Geode Capital Management LLC, Renaissance Technologies LLC, New York State Common Retirement Fund and State of Wisconsin Investment Board. View Insider Buying and Selling for Fate Therapeutics. How do I buy shares of Fate Therapeutics? Shares of FATE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Fate Therapeutics' stock price today? One share of FATE stock can currently be purchased for approximately $18.74. How big of a company is Fate Therapeutics? Fate Therapeutics has a market capitalization of $1.22 billion and generates $4.74 million in revenue each year. The biopharmaceutical company earns $-66,600,000.00 in net income (profit) each year or ($1.19) on an earnings per share basis. Fate Therapeutics employs 104 workers across the globe. What is Fate Therapeutics' official website? The official website for Fate Therapeutics is http://www.fatetherapeutics.com. How can I contact Fate Therapeutics? Fate Therapeutics' mailing address is 3535 GENERAL ATOMICS COURT SUITE 200, SAN DIEGO CA, 92121. The biopharmaceutical company can be reached via phone at 858-875-1800 or via email at [email protected] MarketBeat Community Rating for Fate Therapeutics (NASDAQ FATE)Community Ranking: 3.1 out of 5 ( )Outperform Votes: 305 (Vote Outperform)Underperform Votes: 188 (Vote Underperform)Total Votes: 493MarketBeat's community ratings are surveys of what our community members think about Fate Therapeutics and other stocks. Vote "Outperform" if you believe FATE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe FATE will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/20/2019 by MarketBeat.com StaffFeatured Article: What is Green Investing? Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.